SCHEMBL14217443

SCHEMBL14217443

CNC(=O)c1cccc(C(=O)Nc2ccc(NC(=O)Nc3ccc(Cl)c(CF)c3)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 3/20 0.53
MAPT P10636 5/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
SIRT1 Q96EB6 2/20 0.46
HPSE Q9Y251 1/20 0.45
RAB9A P51151 6/20 0.45
NPC1 O15118 5/20 0.45
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
CBS P35520 1/20 0.44
GAA P10253 1/20 0.44
KDM4E B2RXH2 1/20 0.44
PKM P14618 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14217444 0.94 HPSE (0.54) RAF1MAPTLMNASMN1; SMN2MEN1
SCHEMBL10202245 0.86 KMT2A (0.47) RAF1MAPTMEN1KMT2ASIRT1
SCHEMBL13857369 0.85 MEN1 (0.58) MAPTLMNASMN1; SMN2MEN1KMT2A
SCHEMBL10199829 0.81 RAF1 (0.77) RAF1MAPTLMNAMEN1KMT2A
SCHEMBL10202250 0.81 HPSE (0.54) MAPTMEN1KMT2ASIRT1HPSE
SCHEMBL626988 0.76 RAF1 (0.73) RAF1MAPTLMNARAB9AGAA
SCHEMBL17664545 0.76 RAB9A (0.57) MAPTLMNASMN1; SMN2MEN1KMT2A
SCHEMBL27576035 0.75 HPSE (0.74) MEN1KMT2ASIRT1HPSERAB9A
SCHEMBL15798482 0.73 EPHX1 (0.69) MAPTLMNAMEN1KMT2ARAB9A
SCHEMBL10201086 0.73 RAF1 (0.73) RAF1MEN1KMT2AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108672-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors BAYER HEALTHCARE LLC 2008-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108672-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors BRAF, RAF1, ARAF RAF1 2/4885MAPT 2299/4885LMNA 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.